GI surgeons predict ulcerative colitis drug market future — Takeda, Janssen, Pfizer-Hospira tapped for growth

Spherix Global Insights surveyed 103 gastroenterologists on their thoughts on the ulcerative colitis prescription market.

Here's what you should know:

1. The providers projected significant growth for Takeda's Entyvio, Janssen's Simponi and Pfizer/Hospira's Inflectra.

2. Gastroenterologists believe Entyvio and Simponi's market shares will grow because current users will continue to utilize the drugs, while Inflectra's market share will be boosted by a growing user base.

3. Insurance mandates are limiting Inflectra's general adoption. It's expected payers will encourage providers to prescribe Inflectra in the coming months.

4. Providers are more comfortable prescribing a newly approved irritable bowel syndrome drug than a novel monoamine oxidase inhibitor.

5. Providers are more familiar with Pfizer's Xeljanz than market alternatives like Celgene's Mongersen and Ozanimod or Roche/Genentech's Etrolizumab.

More articles on gastroenterology: 
Effector, Pfizer, Merck partner to test novel immuno-oncology agents in CRC — 4 key notes
GI center to know: Gastroenterology Consultants of Southwest Virginia
Sucampo Pharmaceuticals aims to grow Amitiza line — 4 key notes

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months